Murakawa T, Nakajima J, Kohno T, Tanaka M, Matsumoto J, Takeuchi E, Takamoto S
Department of Cardiothoracic Surgery, Faculty of Medicine, University of Tokyo, Japan.
Jpn J Thorac Cardiovasc Surg. 2000 Feb;48(2):89-95. doi: 10.1007/BF03218097.
The biological behavior of thymoma and its prognosis after surgical intervention remain still controversial. The efficacy of surgical treatment for thymoma was investigated by examining long-term follow-up data.
Follow-up data for patients undergoing surgical resection of histopathologically-confirmed thymoma between 1954 and 1997 were obtained and were retrospectively analyzed. Clinical staging was based on Masaoka's staging system, and histological classification on Rosai's proposed criteria.
Data for 140 patients were collected. Sixty-four patients had stage I, 32 had stage II, 28 had stage III, and 16 had stage IV thymoma. There were significant differences in survival between patients with stage I and stage III, stage I and stage IV and stage II and stage III disease, but not between those with stage I thymoma and stage II thymoma. No significant difference in survival was observed between the 56 patients with myasthenia gravis (MG) and the 84 without MG. The 38 patients classified as having a predominantly-epithelial thymoma had a poorer prognosis than the 41 with a predominantly-lymphocytic thymoma. Until 1975, there were four patients with stage I thymomas who later showed recurrence, compared with 21 among those with stage II, III and IV diseases. Since 1976, extended thymectomy with thymomectomy under median sternotomy has been adopted as the standard operation for a thymoma, and there has been no recurrence in stage I patients.
Patients with stage III or IV invasive thymoma have a poorer prognosis and a higher recurrence rate than those with encapsulated thymoma, and patients with a predominantly-epithelial thymoma have a poorer prognosis than those with a predominantly-lymphocytic thymoma. Extended thymectomy with thymomectomy under median sternotomy can be considered as adequate treatment for a stage I thymoma. Myasthenia gravis does not appear to affect the prognosis of patients with a thymoma.
胸腺瘤的生物学行为及其手术干预后的预后仍存在争议。通过检查长期随访数据来研究胸腺瘤手术治疗的疗效。
获取1954年至1997年间接受组织病理学确诊胸腺瘤手术切除患者的随访数据,并进行回顾性分析。临床分期基于Masaoka分期系统,组织学分类基于Rosai提出的标准。
收集了140例患者的数据。64例为Ⅰ期胸腺瘤,32例为Ⅱ期,28例为Ⅲ期,16例为Ⅳ期。Ⅰ期与Ⅲ期、Ⅰ期与Ⅳ期以及Ⅱ期与Ⅲ期疾病患者的生存率存在显著差异,但Ⅰ期胸腺瘤患者与Ⅱ期胸腺瘤患者之间无显著差异。56例重症肌无力(MG)患者与84例非MG患者的生存率无显著差异。38例主要为上皮型胸腺瘤患者的预后比41例主要为淋巴细胞型胸腺瘤患者差。1975年前,有4例Ⅰ期胸腺瘤患者后来出现复发,而Ⅱ期、Ⅲ期和Ⅳ期疾病患者中有21例复发。自1976年以来,在正中胸骨切开术下行扩大胸腺切除术加胸腺瘤切除术已被用作胸腺瘤的标准手术,Ⅰ期患者未再出现复发。
Ⅲ期或Ⅳ期浸润性胸腺瘤患者的预后比包膜完整的胸腺瘤患者差,复发率更高,主要为上皮型胸腺瘤患者的预后比主要为淋巴细胞型胸腺瘤患者差。在正中胸骨切开术下行扩大胸腺切除术加胸腺瘤切除术可被视为Ⅰ期胸腺瘤的充分治疗方法。重症肌无力似乎不影响胸腺瘤患者的预后。